Skip to main content
Figure 4 | Molecular Cancer

Figure 4

From: Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin

Figure 4

Representation of the domains of the MUC5AC glycoprotein with reactive epitopes indicated for several anti-MUC5AC MAbs. (Derived from references [22, 23, 28]). Data derived by transfection with plasmid vectors containing the cDNA of the 3’-end of MUC5AC, along with derivative cDNA vectors obtained by restriction enzyme digestion, have identified the location of specific epitopes for anti-MUC5AC MAbs employed in the current studies. Specific blocking studies (Figures 3A and B) suggest the PAM4-epitope resides within the cysteine-rich C-terminus domain.

Back to article page

Molecular Cancer

ISSN: 1476-4598